Method for producing liver organoid comprising maturation of liver organoid derived from human pluripotent stem cells, and liver organoid produced therefrom
The production of liver organoids from human pluripotent stem cells without extracellular matrices enhances drug metabolism and transport functions, addressing the limitations of existing methods and providing a cost-effective, clinically relevant model for drug toxicity evaluation.
Patent Information
- Application Number
- PCT/KR2023/010370
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2023-07-19
- Publication Date
- 2024-11-28
AI Technical Summary
Current liver organoid production methods using extracellular matrices are limited by high production costs, batch-to-batch variability, and the inability to fully replicate human liver drug metabolism and transport functions, making them unsuitable for drug toxicity evaluation.
A method for producing liver organoids from human pluripotent stem cells using a maturation medium without extracellular matrix, utilizing a 3D cell culture device to enhance drug metabolizing enzyme expression and function, specifically involving subculturing and culturing steps with defined growth factors and conditions.
The method results in liver organoids with improved drug metabolism and transport functions, mimicking human liver physiology, suitable for drug toxicity evaluation and clinical research, and reduces reliance on costly extracellular matrices.
Smart Images

Figure KR2023010370_28112024_PF_FP_ABST
Abstract
Description
Method for producing liver organoids including maturation of liver organoids derived from human pluripotent stem cells and liver organoids produced therefrom
[0001] The present invention relates to a method for producing liver organoids including maturation of liver organoids derived from human pluripotent stem cells, and to liver organoids produced therefrom.
[0002] The liver is a central organ of metabolic and physiological homeostasis, with diverse functions such as metabolism, protein synthesis, bile production, and red blood cell removal. Hepatocytes, parenchymal liver cells, are primarily responsible for maintaining liver homeostasis and are therefore targets of numerous diseases. Despite recent technological advances in disease modeling of liver failure, models of congenital and progressive metabolic diseases that can lead to end-stage liver failure remain in demand. Furthermore, because the liver possesses a unique function in drug detoxification, models that mimic human hepatocytes are essential for drug metabolism and toxicity assessment in drug development. Current in vitro and in vivo liver models have significantly contributed to elucidating the pathogenesis of liver disease and assessing drug safety, but they still fail to fully reflect human liver physiology. Animal models also have limitations in predicting drug toxicity due to interspecies differences. Furthermore, primary human hepatocytes (PHHs) are the gold standard for in vitro liver models. However, their use is limited due to limited accessibility to human liver tissue and functional instability. Furthermore, liver cancer cells, unlike normal cells, lack full expression or reduced function of drug-metabolizing enzymes, making them unsuitable for drug toxicity assessment. Therefore, it is necessary to develop a liver model that can mimic human liver metabolism while retaining drug-metabolizing capacity.
[0003] Meanwhile, organoids are organ-specific cell aggregates created by 3D culturing, aggregating, or recombining stem cells. They are capable of self-renewal and are also called "mini-organs" or "organoids." Organoids are very useful for basic research because they resemble actual organs and can be used to conduct in vitro studies that are difficult to implement in animal models, such as molecular signaling regulation. They are also a technology that can be very useful in various fields, such as human development, establishing disease models, evaluating drug efficacy and screening, developing drug toxicity assessment platforms, and developing cell therapy agents. Human liver organoids were first developed from adult human liver tissue using culture medium containing R-Spondin 1. Primary human hepatocytes (PHH) were also applied to 3D organoid culture, and the generation of liver buds and liver organoids from human pluripotent stem cells (hPSCs) was reported. Liver organoids (hHO) derived from human pluripotent stem cells have been proposed as in vitro models for disease modeling, including genetic and metabolic disorders, cell therapy, and drug toxicity testing. Research is currently underway to establish various organoids, and liver organoids have also been developed. Prior art methods for producing liver organoids include generating liver organoids through expansion stages derived from definitive endoderm and hepatic endoderm, demonstrating that the generated liver organoids have proliferative capacity and confirming their ability to model and regenerate citrullinemia type 1 and alcoholic liver injury (Akbari et al. (2019). Robust, Long-Term Culture of Endoderm-Derived Hepatic Organoids for Disease Modeling. Stem Cell Reports 13, 627-641.; Wang et al. (2019).There are also literatures (Mun et al. (2019). Generation of expandable human pluripotent stem cell derived hepatocyte-like liver organoids. J Hepatol 71, 970-985.) that produced liver organoids by an expansion step derived from 3D spherical hPSC-derived mature hepatocyte-like cells (HLCs) and proposed liver organoids as a model to evaluate drug-induced hepatic steatosis. Cell Res 29, 1009-1026.)
[0004] However, currently known liver organoids have limitations in reproducing drug metabolism and transport functions. As in vitro models for drug toxicity and efficacy testing, liver organoids must be reproducibly produced and exhibit drug metabolism and transport functions similar to those of adult liver and primary hepatocytes (PHH). To achieve this, it is necessary to generate liver organoids that express hepatic cytochrome P450 (CYP450) proteins, a superfamily of enzymes primarily responsible for the biotransformation of most pharmaceuticals and xenobiotics.
[0005] Furthermore, while organoid models have been proposed as an alternative to toxicity assessment models due to their similar characteristics to in vivo organs, liver organoids developed to date do not possess the drug-metabolizing ability required for toxicity assessment models to reach the level of human primary hepatocytes. Most organoid production uses static methods using extracellular matrix, and the high production cost of the extracellular matrix is a financial burden for producers, and it is difficult to supply since it is produced overseas. Furthermore, the extracellular matrix contains unknown components due to its origin from mouse cancer cells, which can significantly affect the reproducibility of organoid production depending on product batch-to-batch variations and usage environments (temperature or concentration). Therefore, there is a high possibility that this could hinder the future use of organoids in toxicity assessments.
[0006] Accordingly, there is a need for the development of liver organoids that can function as a toxicity screening platform through detailed functional analyses such as drug metabolism and transport, and a technology for maturation and production of liver organoids from human pluripotent stem cells (hPSCs) without the need for an extracellular matrix.
[0007] The present invention aims to solve the above-mentioned problems and other problems related thereto.
[0008] The purpose of the present invention is to provide a method for maturing a liver organoid, which comprises a step of maturing a liver endoderm organoid differentiated from a human pluripotent stem cell (hPSC) into a hepatic organoid (HO) by culturing the organoid in a maturation medium that does not contain an extracellular matrix.
[0009] Another object of the present invention is to provide a method for producing a liver organoid, which comprises the step of producing a liver organoid by culturing a liver endoderm organoid differentiated from a human pluripotent stem cell in a medium that does not contain an extracellular matrix.
[0010] Another object of the present invention is to provide a liver organoid produced by the method for producing the liver organoid.
[0011]
[0012] The technical problem to be achieved according to the technical idea of the invention disclosed in this specification is not limited to the problem to solve the above-mentioned problem, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.
[0013] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0014]
[0015] As one aspect to achieve the above object, the present invention provides a method for producing liver organoids including maturation of liver organoids derived from human pluripotent stem cells, and liver organoids produced therefrom. Specifically, the present invention provides a method for producing liver organoids with excellent expression and function of drug metabolizing enzymes, and liver organoids produced therefrom, by including a step of maturation using a 3D cell culture medium without physically disrupting cells and without an extracellular matrix (Matrigel), unlike conventional liver organoid production methods.
[0016] As another aspect for achieving the above object, the present invention provides a method for maturing a liver organoid, including a step of maturing a liver endoderm organoid differentiated from a human pluripotent stem cell (hPSC) into a hepatic organoid (HO) by culturing the organoid in a maturation medium that does not contain an extracellular matrix.
[0017] In the present invention, the 'human pluripotent stem cell (hPSC)' refers to a stem cell that can differentiate into almost all types of cells that constitute the endoderm, mesoderm, and ectoderm. The 'human pluripotent stem cell' of the present invention may be a human embryonic stem cell (hESC) or a human induced pluripotent stem cell (hiPSC), but is not limited thereto.
[0018] In the present invention, the 'extracellular matrix' refers to a collection of biopolymers that fill the gaps between cells to physically support tissues or surround cells to create an environment in which cells can survive robustly. The extracellular matrix of the present invention may be Matrigel, Cultrex BME (Basement Membrane Extract), or Geltrex Matrix, preferably Matrigel, and specifically Matrigel GFR (Growth Factor Reduced), but is not limited thereto.
[0019] In the present invention, a step of subculturing hepatic endoderm organoids may be further included prior to culturing in a maturation medium that does not include the extracellular matrix.
[0020] The step of subculturing the hepatic endoderm organoids may be performed by adding BMP7 to the hepatic endoderm organoid maintenance medium (Expansion Medium, EM medium), and culturing may be performed for 1 to 3 days after adding BMP7, and preferably for 2 days. In addition, the BMP7 may be contained in an amount of 10 to 35 ng / ml, preferably in an amount of 20 to 30 ng / ml, and more preferably in an amount of 25 ng / ml.
[0021] After subculturing the above hepatic endoderm organoids, the step of maturing the hepatic endoderm organoids into liver organoids may include adding BMP7 to an EM medium that does not contain an extracellular matrix, adding the spun-down hepatic endoderm organoids, and then placing them in a bioreactor and culturing them at 37°C and 5% CO2 for 2 to 4 days, preferably culturing them for 3 days. In addition, the culture may be performed at 40 to 100 rpm, preferably 50 to 90 rpm, and more preferably 80 rpm.
[0022] The EM medium without the above extracellular matrix specifically contains fibroblast growth factor 10 (FGF10), hepatocyte growth factor (HGF), nicotinamide, [Leu 15 ]-Gastrin I human, N-acetyl-L-cysteine, A83-01, Forskolin, and CHIR99021, but are not limited thereto.
[0023] The above FGF10 may be included in the EM medium at 30 to 70 ng / ml, preferably 40 to 60 ng / ml, and more preferably 50 ng / ml, but is not limited thereto.
[0024] The above HGF may be included in the EM medium at 5 to 45 ng / ml, preferably 15 to 35 ng / ml, more preferably 25 ng / ml, but is not limited thereto.
[0025] The nicotinamide may be included in the EM medium at 1 to 20 mM, preferably 5 to 15 mM, and more preferably 10 mM, but is not limited thereto.
[0026] Above [Leu 15 ]-Gastrin I human may be included in the EM medium at 1 to 20 nM, preferably 5 to 15 nM, more preferably 10 nM, but is not limited thereto.
[0027] The above N-acetyl-L-cysteine may be included in the EM medium at 0.25 to 2.25 mM, preferably 0.5 to 2 mM, more preferably 1.25 mM, but is not limited thereto.
[0028] The above A83-01 may be included in the EM medium at 1 to 9 μM, preferably 3 to 7 μM, more preferably 5 μM, but is not limited thereto.
[0029] The Forskolin may be included in the EM medium at a concentration of 1 to 20 μM, preferably 5 to 15 μM, and more preferably 10 μM, but is not limited thereto.
[0030] The CHIR99021 may be included in the EM medium at 1 to 5 μM, preferably 2 to 4 μM, and more preferably 3 μM, but is not limited thereto.
[0031] After the above culturing, a step of performing additional culturing after replacing with a liver organoid differentiation medium (DM medium) may be included. Preferably, the DM medium may not contain an extracellular matrix, and specifically, may not contain Matrigel GFR. The culturing may be performed at 37°C, 5% CO2 for 13 to 17 days, preferably 14 to 16 days, more preferably 15 days, and the medium may be replaced at intervals of 2 to 4 days. In addition, the culturing may be performed at 40 to 80 rpm, preferably 50 to 70 rpm, and more preferably 60 rpm.
[0032] The DM medium may include, but is not limited to, bone morphogenetic protein 7 (BMP7), fibroblast growth factor 19 (FGF19), hepatocyte growth factor (HGF), N-acetyl-L-cysteine, A83-01, DAPT, and dexamethasone.
[0033] The above FGF19 may be included in the DM medium at 80 to 120 ng / ml, preferably 90 to 110 ng / ml, and more preferably 100 ng / ml, but is not limited thereto.
[0034] The above HGF may be included in the DM medium at 5 to 45 ng / ml, preferably 15 to 35 ng / ml, more preferably 25 ng / ml, but is not limited thereto.
[0035] The above N-acetyl-L-cysteine may be included in the DM medium at 0.25 to 2.25 mM, preferably 0.5 to 2 mM, more preferably 1.25 mM, but is not limited thereto.
[0036] The above A83-01 may be included in the DM medium at 0.1 to 0.9 μM, preferably 0.3 to 0.7 μM, more preferably 0.5 μM, but is not limited thereto.
[0037] The above DAPT may be included in the DM medium at 1 to 30 uM, preferably 5 to 20 uM, more preferably 10 uM, but is not limited thereto.
[0038] The above dexamethasone may be included in the DM medium at 1 to 5 μM, preferably 2 to 4 μM, more preferably 3 μM, but is not limited thereto.
[0039] As one aspect for achieving the above object, the present invention provides a method for producing a liver organoid, comprising the step of producing a liver organoid by culturing a liver endoderm organoid differentiated from a human pluripotent stem cell in a medium not containing an extracellular matrix.
[0040] The above ‘human pluripotent stem cells’ and ‘extracellular matrix’ are as described above.
[0041] In the present invention, a step of subculturing hepatic endoderm organoids may be further included prior to culturing in a medium that does not contain the extracellular matrix.
[0042] The step of subculturing the above-mentioned hepatic endoderm organoids may be performed by adding BMP7 to EM medium, and the culture may be performed for 1 to 3 days after adding BMP7, and preferably for 2 days. In addition, the BMP7 may be contained in an amount of 10 to 35 ng / ml, preferably in an amount of 20 to 30 ng / ml, and more preferably in an amount of 25 ng / ml.
[0043] After subculturing the above hepatic endoderm organoids, the step of manufacturing the hepatic endoderm organoids into liver organoids may include adding BMP7 to an EM medium that does not contain an extracellular matrix, adding the spun-down hepatic endoderm organoids, and then placing the organoids in a bioreactor and culturing them at 37°C and 5% CO2 for 2 to 4 days, preferably culturing them for 3 days. In addition, the organoids may be cultured at 40 to 100 rpm, preferably 50 to 90 rpm, and more preferably 80 rpm.
[0044] After the above culturing, a step of performing additional culturing after replacing with a liver organoid differentiation medium (DM medium) may be included. Preferably, the DM medium may not contain an extracellular matrix, and specifically, may not contain Matrigel GFR. The culturing may be performed at 37°C, 5% CO2 for 13 to 17 days, preferably 14 to 16 days, more preferably 15 days, and the medium may be replaced at intervals of 2 to 4 days. In addition, the culturing may be performed at 40 to 80 rpm, preferably 50 to 70 rpm, and more preferably 60 rpm.
[0045] In the present invention, the method for producing a liver organoid comprises: (a) a step of differentiating human pluripotent stem cells (hPSCs) into definitive endoderm cells (DE); (b) a step of differentiating the definitive endoderm cells of step (a) into hepatic endoderm cells (HE); and (c) a step of differentiating the hepatic endoderm cells of step (b) into hepatic endoderm organoids (HEO); and culturing the hepatic endoderm organoids obtained through the step of differentiating the hepatic endoderm cells of step (b) into hepatic endoderm organoids (HEO) in a medium that does not contain an extracellular matrix to produce a liver organoid.
[0046] In the present invention, the 'endoderm' of step (a) is one of the three germ layers of the early embryonic stage, and forms the inner membrane of three accessory organs (teeth, tongue, and glandular organs) that develop toward the tail of the stomach.
[0047] In the present invention, the step of differentiating into a complete endoderm cell in step (a) is to differentiate human pluripotent stem cells into mTeSR TM -E8 TM This may include, but is not limited to, a step of culturing the culture medium for one day.
[0048] In the present invention, the step of differentiating into a definitive endoderm cell in step (a) may include a step of culturing human pluripotent stem cells cultured for 22 to 30 hours in a definitive endoderm (DE) differentiation medium 1 for one day, and then culturing them in an endoderm (DE) differentiation medium 2 for 3 to 6 days.
[0049] The above endoderm (DE) differentiation medium 1 may include, but is not limited to, RPMI-1640 containing 0.1% BSA, 1% B27 supplement, Activin A, Sodium butyrate, and CHIR99021.
[0050] The above activin A may be included in the endoderm differentiation medium 1 at 30 to 70 ng / ml, preferably 40 to 60 ng / ml, more preferably 50 ng / ml, but is not limited thereto.
[0051] The sodium butyrate may be included in the endoderm differentiation medium 1 in an amount of 0.1 to 0.9 mM, preferably 0.3 to 0.7 mM, and more preferably 0.5 mM, but is not limited thereto.
[0052] The CHIR99021 may be included in the endoderm differentiation medium 1 at 1 to 5 uM, preferably 2 to 4 uM, more preferably 3 uM, but is not limited thereto.
[0053] The above endoderm (DE) differentiation medium 2 may include, but is not limited to, RPMI-1640 containing 0.1% BSA, 1% B27 supplement, Activin A, and sodium butyrate.
[0054] The above activin A may be included in the endoderm differentiation medium 2 at 30 to 70 ng / ml, preferably 40 to 60 ng / ml, more preferably 50 ng / ml, but is not limited thereto.
[0055] The sodium butyrate may be included in the endoderm differentiation medium 2 at 0.05 to 1.05 mM, preferably 0.09 to 0.11 mM, and more preferably 0.1 mM, but is not limited thereto.
[0056] In the present invention, the step of differentiating into hepatic endoderm cells in step (b) may include a step of culturing endoderm cells in hepatic endoderm (HE) differentiation medium for 4 to 6 days, preferably culturing for 4 days, and may include a process of replacing the medium at intervals of 22 to 26 hours.
[0057] The above hepatic endoderm (HE) differentiation medium may include, but is not limited to, RPMI-1640 containing 0.1% BSA, 1% B27 supplement, Bone Morphogenetic Protein 4 (BMP4), and SB431542.
[0058] The above BMP4 may be included in the hepatic endoderm differentiation medium at 30 to 70 ng / ml, preferably 40 to 60 ng / ml, more preferably 50 ng / ml, but is not limited thereto.
[0059] The above SB431542 may be included in the hepatic endoderm differentiation medium at 5 to 15 μM, preferably 8 to 12 μM, more preferably 10 μM, but is not limited thereto.
[0060] After differentiation in step (b) above is performed, the EpCAM (Epithelial cell adhesion molecule) positive population is analyzed through flow cytometry, and if the EpCAM-positive cells are 95% or more, the process can proceed to step (c).
[0061] In the present invention, the step of differentiating into hepatic endoderm organoids (HE0) in step (c) may include a step of culturing hepatic endoderm cells that have completed differentiation in step (b) in hepatic endoderm organoid production medium (GM medium).
[0062] The GM medium contained Advanced DMEM / F12 containing 10 mM HEPES (Hydroxyethyl piperazine Ethane Sulfonic acid), 1% GlutaMAX, 100 U / ml Penicillin-Streptomycin, 0.1% BSA, 1% B27 supplement minus Vitamin A, 1% N2 supplement, Fibroblast growth factor 10 (FGF10), Hepatocyte growth factor (HGF), nicotinamide, [Leu 15 ]-Gastrin I human, N-acetyl-L-cysteine, A83-01, Forskolin, CHIR99021 and Matrigel GFR (growth factor reduced) may include, but are not limited to.
[0063] The above FGF10 may be included in the GM medium at 30 to 70 ng / ml, preferably 40 to 60 ng / ml, more preferably 50 ng / ml, but is not limited thereto.
[0064] The above HGF may be included in the GM medium at 5 to 45 ng / ml, preferably 15 to 35 ng / ml, more preferably 25 ng / ml, but is not limited thereto.
[0065] The nicotinamide may be included in the GM medium at 1 to 20 mM, preferably 5 to 15 mM, and more preferably 10 mM, but is not limited thereto.
[0066] Above [Leu 15 ]-Gastrin I human may be included in the GM medium at 1 to 20 nM, preferably 5 to 15 nM, more preferably 10 nM, but is not limited thereto.
[0067] The above N-acetyl-L-cysteine may be included in the GM medium at 0.25 to 2.25 mM, preferably 0.5 to 2 mM, more preferably 1.25 mM, but is not limited thereto.
[0068] The above A83-01 may be included in the GM medium at 1 to 9 μM, preferably 3 to 7 μM, more preferably 5 μM, but is not limited thereto.
[0069] The above Forskolin may be included in the GM medium at 1 to 20 μM, preferably 5 to 15 μM, more preferably 10 μM, but is not limited thereto.
[0070] The CHIR99021 may be included in the GM medium at a concentration of 1 to 5 μM, preferably 2 to 4 μM, and more preferably 3 μM, but is not limited thereto.
[0071] The above Matrigel GFR may be included in the GM medium at 0.2 to 0.8 mg / ml, preferably 0.3 to 0.7 mg / ml, more preferably 0.5 mg / ml, but is not limited thereto.
[0072] Culturing of hepatic endoderm cells in the above GM medium may be carried out for 10 to 18 days, preferably 12 to 16 days, and more preferably 14 days. During the above culturing, the medium may be replaced at intervals of 2 to 4 days, preferably 3 days.
[0073] In the present invention, after the step (c), a step of subculturing the hepatic endoderm organoids may be further included.
[0074] The subculturing step may include leaving the medium on ice for 10 to 30 minutes to separate the Matrigel and hepatic endoderm organoids in the medium, spinning down at 800 to 1200 rpm for 30 seconds to 2 minutes to remove the supernatant. After removing the supernatant, the method may further include adding DPBS (Dulbecco's phosphate-buffered saline) to loosen the pellet, spinning down at 800 to 1200 rpm for 30 seconds to 2 minutes to remove the supernatant once again, and adding 0.5 to 2 ml of an enzyme to loosen the pellet. The enzyme may be TrypLE Express, Accutase, or 0.25% trypsin-EDTA, but preferably TrypLE Express, and more preferably 1 ml of TrypLE Express. After adding the enzyme to loosen the pellet, leave it in a water bath at 37°C for 3 to 7 minutes, pipette again to loosen all the pellets, and then add basal medium (Organoid basal medium, OB medium) containing Advanced DMEM / F12 with 10 mM HEPES, 1% GlutaMAX, 100 U / ml penicillin-streptomycin, and 0.1% BSA, spin down, and remove the supernatant.
[0075] The above subculture may include a step of culturing the hepatic endoderm organoids in a maintenance medium for hepatic endoderm organoids (EM medium) after removing the supernatant.
[0076] The EM medium may be the same as the GM medium. Specifically, the EM medium may contain fibroblast growth factor 10 (FGF10), hepatocyte growth factor (HGF), nicotinamide, [Leu 15 ]-Gastrin I human, N-acetyl-L-cysteine, A83-01, Forskolin, CHIR99021 and Matrigel GFR (growth factor reduced) may include, but are not limited to.
[0077] The above FGF10 may be included in the EM medium at 30 to 70 ng / ml, preferably 40 to 60 ng / ml, and more preferably 50 ng / ml, but is not limited thereto.
[0078] The above HGF may be included in the EM medium at 5 to 45 ng / ml, preferably 15 to 35 ng / ml, more preferably 25 ng / ml, but is not limited thereto.
[0079] The nicotinamide may be included in the EM medium at 1 to 20 mM, preferably 5 to 15 mM, and more preferably 10 mM, but is not limited thereto.
[0080] Above [Leu 15 ]-Gastrin I human may be included in the EM medium at 1 to 20 nM, preferably 5 to 15 nM, more preferably 10 nM, but is not limited thereto.
[0081] The above N-acetyl-L-cysteine may be included in the EM medium at 0.25 to 2.25 mM, preferably 0.5 to 2 mM, more preferably 1.25 mM, but is not limited thereto.
[0082] The above A83-01 may be included in the EM medium at 1 to 9 μM, preferably 3 to 7 μM, more preferably 5 μM, but is not limited thereto.
[0083] The Forskolin may be included in the EM medium at a concentration of 1 to 20 μM, preferably 5 to 15 μM, and more preferably 10 μM, but is not limited thereto.
[0084] The CHIR99021 may be included in the EM medium at 1 to 5 μM, preferably 2 to 4 μM, and more preferably 3 μM, but is not limited thereto.
[0085] The above Matrigel GFR may be included in the EM medium at 0.2 to 0.8 mg / ml, preferably 0.3 to 0.7 mg / ml, more preferably 0.5 mg / ml, but is not limited thereto.
[0086] The passage interval of the above subculture may vary slightly depending on the seeding density, but may be at intervals of 3 to 8 days, preferably at intervals of 4 to 7 days, and more preferably at intervals of 5 to 6 days, and the medium may be replaced at intervals of 2 to 3 days. In addition, the split ratio may be at intervals of 1:4 to 1:10, preferably at intervals of 1:5 to 1:10, and more preferably at intervals of 1:6 to 1:10.
[0087] In the present invention, after the step (c), a step of cryopreserving and thawing the hepatic endoderm organoid may be further included.
[0088] The above cryopreservation step may include a process of leaving on ice for 10 to 30 minutes to separate the Matrigel and organoids in the medium, spinning down at 800 to 1200 rpm for 30 seconds to 1 minute to remove the supernatant. After removing the supernatant, the process may further include adding DPBS (Dulbecco's phosphate-buffered saline) to loosen the pellet, spinning down at 800 to 1200 rpm for 30 seconds to 1 minute to remove the supernatant once again, and adding 0.5 to 2 ml of an enzyme to loosen the pellet. The enzyme may be TrypLE Express, Accutase, or 0.25% trypsin-EDTA, but preferably TrypLE Express, and more preferably, 1 ml of TrypLE Express may be added. The process may include adding the enzyme to loosen the pellet, leaving it in a water bath for 1 to 3 minutes, pipetting again to loosen all the pellets, adding OB basic medium, spinning down at 800 to 1200 rpm for 2 to 4 minutes, and removing the supernatant. The step of cryopreserving the hepatic endoderm organoid of the present invention may enable cryopreservation as a single-cell organoid without the need to fragment the organoid.
[0089]
[0090] As another aspect for achieving the above purpose, the present invention provides a liver organoid produced by the method for producing the liver organoid.
[0091] In the present invention, the liver organoid may express cytochrome P450 (CYP450) at a high level. Specifically, the liver organoid may express cytochrome P450 at a higher level than liver organoids differentiated by a conventional method in a medium containing an extracellular matrix without using a bioreactor.
[0092] The above cytochrome P450 is a superfamily of enzymes that have heme as a prosthetic group, and is known as a representative catalytic enzyme that performs oxidative metabolism for various exogenous substances such as most drugs and environmental substances, or endogenous substances such as steroids and lipids. The main function of CYP450 enzymes can be said to be a single oxidation reaction (mono-oxygenation or mixed-function oxidase reaction) for various substrates, and this reaction requires oxygen molecules and reducing substances of NADPH. One atom of the oxygen molecule combines with the substrate to be oxidized, and the other atom is reduced to water. The microsomal CYP450 system, which is contained in large quantities in liver cells, is where CYP450 enzymes are located in the membrane of the endoplasmic reticulum, and perform oxidation reactions by receiving electrons from NADPH-P450 reductase that is also present in the membrane.
[0093] In the present invention, the cytochrome P450 may be at least one selected from the group consisting of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5, and preferably, at least one selected from the group consisting of CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5.
[0094] The above CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 are a type of cytochrome P450 and may have the function of primarily metabolizing 95% of the drugs being used.
[0095] In the present invention, the liver organoid may have an increased expression level of major liver marker genes such as albumin (ALB), alpha-1 antitrypsin (AAT), hepatocyte nuclear factor 4 alpha (HNF4A), tyrosine aminotransferase (TAT), tryptophan 2,3-dioxygenase (TDO2), glucose-6-phosphate (G6P), phosphoenolpyruvate carboxykinase 2 (PCK2), or asialoglycoprotein receptor 1 (ASGR1), and a drug transporter gene such as multidrug resistance protein 1 (Multidrug Resistance 1, It may be an increase in the expression level of multidrug resistance-associated protein 2 (MRP2), bile salt export pump (BSEP), sodium taurocholate co-transporting polypeptide (NTCP), breast cancer resistance protein (BCRP), organic anion-transporting polypeptide 1B1 (OATP1B1), or organic anion-transporting polypeptide 1B3 (OATP1B3).Specifically, the liver organoids may express the liver marker gene or drug transporter gene at a higher level than liver organoids differentiated by a conventional method in a medium containing an extracellular matrix without using a bioreactor.
[0096] The above extracellular matrix may be Matrigel, Cultrex BME (Basement Membrane Extract), or Geltrex Matrix, preferably Matrigel, and specifically Matrigel GFR (Growth Factor Reduced), but is not limited thereto.
[0097]
[0098] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
[0099] The method for manufacturing liver organoids according to the present invention, unlike conventional liver organoid manufacturing methods, does not physically disrupt cells, but includes a step of isolating cells into single cells by treating them with enzymes and differentiating them using a 3D cell culture medium (Bioreactor) without an extracellular matrix (Matrigel), thereby enabling easy procurement and manufacturing of human-tailored liver organoids. Since the liver organoids are composed of cells that constitute major liver tissues, they exhibit excellent drug metabolism and function, allowing them to mimic the structure of an actual human liver, making them suitable for use in liver disease research or drug safety evaluation. In addition, since they can be manufactured without an extracellular matrix, they can also be utilized in clinical research.
[0100] Figure 1 is a schematic diagram showing the process of producing hepatic endoderm organoids from human pluripotent stem cells (hPSCs).
[0101] Figure 2 is a schematic diagram showing the process of differentiating and producing liver organoids from hepatic endoderm organoids.
[0102] Figure 3 shows the results of observing the degree of liver organoid differentiation according to the number of days for liver organoid differentiation and the use of Matrigel and bioreactor.
[0103] Figure 4 shows the results of confirming the expression levels of ALB, AAT, and HNF4A in liver organoids manufactured according to the conventional liver organoid manufacturing method and the liver organoid manufacturing method using a bioreactor without Matrigel of the present invention.
[0104] Figure 5 shows the results of confirming the expression levels of liver marker genes (Figure 5A), CYP450 genes (Figure 5B), and drug transporter genes (Figure 5C) in liver organoids manufactured according to the conventional liver organoid manufacturing method and the liver organoid manufacturing method using a bioreactor without Matrigel of the present invention. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001)
[0105] Figure 6 shows the results of confirming the expression levels of liver marker genes, CYP450 genes, and drug transporter genes according to the number of days of liver organoid differentiation in liver organoids manufactured according to the existing liver organoid manufacturing method and the liver organoid manufacturing method using the bioreactor of the present invention.
[0106] Figure 7 shows the results of confirming the amount of albumin (Figure 7A) and urea (Figure 7B) secreted from liver organoids manufactured according to the conventional liver organoid manufacturing method and the liver organoid manufacturing method using the bioreactor of the present invention, and the results of measuring CYP activity over time after treating a substrate corresponding to CYP (Figure 7C).
[0107] Figure 8 shows the results of measuring CYP3A4 activity by time zone in liver organoids manufactured according to a conventional liver organoid manufacturing method and a liver organoid manufacturing method using a bioreactor of the present invention, by treating midazolam, a substrate of CYP3A4.
[0108] Hereinafter, the present invention will be described in more detail through the following examples. However, these examples are intended to exemplify the present invention and the scope of the present invention is not limited to these examples.
[0109]
[0110] Example 1. Production of hepatic endoderm organoids
[0111] The general process for producing hepatic endoderm organoids (HEOs) from human pluripotent stem cells (hPSCs) is shown in Figure 1.
[0112] 1.1. Human Pluripotent Stem Cell (hPSC) Seeding: Day -10
[0113] First, human pluripotent stem cells (hPSCs) were seeded at Day -10 based on the time of hepatic endoderm differentiation (Day 0). The human pluripotent stem cell culture medium was TeSR. TM -E8 TM (Stem Cell Technologies) was used.
[0114] Specifically, a 12-well culture plate for seeding was prepared, and 0.5 ml of diluted Matrigel was added to each well, and coating was performed at 37°C for 30 minutes. The Matrigel was used by diluting the original solution of hESC qualified Matrigel (Corning, Cat No. 354277) according to the COA (Certificate of Analysis). During the Matrigel coating, the cultured hPSCs were removed from the incubator and the medium was removed.
[0115] Afterwards, 1 ml of DPBS (Dulbecco's phosphate-buffered saline) (Ca) containing 0.5 mM EDTA 2+ and Mg 2+ The medium containing 2 μM Y-27632 was added and incubated at 37°C for 4 to 5 minutes. After carefully removing the cells from the incubator, the plate was tilted to suction out the EDTA. TeSR containing 2 μM Y-27632 prepared TM -E8 TM Cells were harvested using 1 ml of 12 ml, and the harvested cells were added to 11 ml TeSR containing 2 μM Y-27632. TM -E8 TM The cells were placed in a conical tube and mixed gently by pipetting. The Matrigel-coated plate was removed from the incubator, and all Matrigel was removed by suction. Afterwards, the recovered cells were dispensed at 1 ml per well and cultured in a 37°C, 5% CO2 incubator for one day.
[0116]
[0117] 1.2. Differentiation of human pluripotent stem cells (hPSCs) into definitive endoderm (DE) cells: Day -9 to Day -4
[0118] After preparing 12 ml of Definitive Endoderm (DE) differentiation medium 1 with the composition shown in Table 1 below, the cells were left to incubate at 37°C. After culturing hPSCs for one day, the medium was removed from the incubator and the cells were cultured. 1 ml of the prepared endoderm differentiation medium 1 was added to each well and cultured for 24 hours in a 37°C, 5% CO2 incubator.
[0119] Name composition Endoderm differentiation medium 1 (DE medium 1) RPMI-1640 containing 0.1% BSA and 1% B27 supplement 50 ng / ml Activin A (ActA) 0.5 mM Sodium butyrate 3 μM CHIR99021
[0120]
[0121] After 24 hours, the medium was replaced with endoderm differentiation medium 2 (DE medium 2) having the composition shown in Table 2 below, and cultured in a 37°C, 5% CO2 incubator for 4 days, with the medium replaced every 24 hours.
[0122] Endoderm differentiation medium 2 (DE medium 2) RPMI-1640 containing 0.1% BSA and 1% B27 supplement 50 ng / ml Activin A (ActA) 0.1 mM Sodium butyrate
[0123]
[0124] 1.3. Differentiation from complete endoderm cells to hepatic endoderm cells: Day -4 to Day 0
[0125] After preparing 12 ml of hepatic endoderm (HE) differentiation medium with the composition shown in Table 3 below, the medium was incubated at 37°C, and the cells differentiated into endoderm were removed from the incubator and the medium was removed. 1 ml of the prepared hepatic endoderm differentiation medium was added per well, and the cells were cultured in a 37°C, 5% CO2 incubator for 4 days, and the medium was replaced every 24 hours.
[0126] Endoderm differentiation medium (HE medium) RPMI-1640 containing 0.1% BSA and 1% B27 supplement 50 ng / ml BMP4 10 μM SB431542
[0127] 1.4. Production of Hepatic Endoderm Organoids (HEO): Day 0–Day 14
[0128] The medium (Generation Medium; GM) for hepatic endodermal organoids (HEO) with the composition shown in Table 4 below was prepared at least one day before the experiment.
[0129]
[0130] Endoderm organoid production medium (GM) Advanced DMEM / F12 containing 10 mM HEPES, 1% GlutaMAX, 100 U / ml penicillin-streptomycin, 0.1% BSA, 1% B27 supplement minus vitamin A, 1% N2 supplement 50 ng / ml FGF 10 25 ng / ml HGF 10 mM Nicotinamide 10 nM [Leu 15 ]-Gastrin I human1.25 mM N-acetyl-L-cysteine5 μM A83-0110 μM Forskolin3 μM CHIR990210.5 mg / ml Matrigel GFR (growth factor reduced)
[0131]
[0132] Remove differentiated hepatic endoderm cells (use only 3 to 4 wells in good condition) from the incubator, remove the medium, and Ca 2+ and Mg 2+ The cells were washed once with DPBS medium containing no .
[0133] 500 μl Accutase was added per well and incubated at 37°C for 10 minutes. Cells separated into single cells were transferred to a 15 ml conical tube containing 10 ml organoid basal medium (OB), centrifuged at 1200 rpm for 3 minutes, and the supernatant was removed.
[0134] The cell pellet was resuspended in 1 ml of cold GM medium and transferred to a 1.5 ml tube. Cell counting was then performed and the culture step was performed.
[0135]
[0136] 1.5. Culture of hepatic endoderm organoids
[0137] GM medium for hepatic endoderm organoids was pre-dispensed into 24-well ultra-low attachment plates at 0.5 ml per well. The medium was kept on ice until use and maintained at 4°C to prevent Matrigel gelation.
[0138] After adding 10,000 single hepatic endoderm cells per well, the plates were cultured in a 37°C, 5% CO2 incubator for 14 days. Before placing the plate in the incubator and closing the door, the cells were evenly distributed to prevent clumping and the medium was replaced every 3 days.
[0139] For batch replacement, based on 1 well of a 24-well plate, all the medium containing the organoids cultured in suspension was recovered using 1000P, transferred to a 1.5 ml tube, centrifuged at 1200 rpm for 1 minute, the supernatant was removed, resuspended in 0.5 ml of GM medium for hepatic endoderm organoids (s-HEO) in a new suspension state, and then spread onto the plate again and cultured in a 37°C, 5% CO2 incubator for 3 days.
[0140]
[0141] Example 2. Subculture of hepatic endoderm organoids
[0142] The hepatic endoderm organoids were removed from the incubator and collected using a 1000P microplate into a 15 ml tube, including the medium within the well. The organoids were then placed on ice for further experiments.
[0143] To separate the Matrigel and organoids in the medium, the medium was left on ice for 20 minutes, spun down at 1000 rpm for 1 minute, and the supernatant was removed. 1 ml of DPBS was added and the pellet was loosened by pipetting. The medium was spun down at 1000 rpm for 1 minute, the supernatant was removed, 1 ml of TrypLE Express was added and the pellet was loosened by pipetting. The medium was then left in a 37°C water bath for 5 minutes. After loosening all the pellets by pipetting, 1.5 ml of basal medium was added and spun down at 1000 rpm for 3 minutes.
[0144] A new 24-well ultra-low attachment plate was pre-dispensed with 0.5 ml of fresh HEO maintenance medium (Expansion Medium, EM) per well. The EM medium was prepared with the same composition as the GM medium. After removing the supernatant after the spin-down, 200 μL of ice-cold EM was added to loosen the pellet, and 20 μL was dispensed per well. The plate was cultured in a 37°C, 5% CO2 incubator for 5 to 6 days. Before placing the plate in the incubator and closing the door, the plate was shaken up and down from side to side to evenly distribute the cells so that they do not grow in clumps. The medium was replaced every 3 days.
[0145] Batch replacement was performed by recovering all the medium containing the organoids cultured in suspension using 1000P based on 1 well of a 24-well plate, transferring them to a 1.5 ml tube, centrifuging at the maximum speed of 5000 rpm using a mini centrifuge, removing the supernatant, resuspending with 0.5 ml of new EM medium for HEO, and spreading it back on the plate, and culturing it in a 37°C, 5% CO2 incubator for 3 days.
[0146] The passage interval of the above subculture differed slightly depending on the seeding density, but 5 to 6 days was the optimal interval, and the split ratio was 1:6 to 1:10, but was adjusted depending on the amount of cells.
[0147]
[0148] Example 3. Freezing and thawing of hepatic endoderm organoids
[0149] 3.1. Freeze
[0150] The hepatic endoderm organoids were taken out from the incubator, and all organoids including the medium in the well were collected in a 1.5 ml tube using 1000P, placed on ice, and used for the experiment.
[0151] To separate Matrigel and organoids, the cells were placed on ice for 20 minutes, spun down at maximum speed of 5000 rpm using a mini centrifuge, and the supernatant was removed. 1 ml of DPBS was added and the pellet was loosened by pipetting. The cells were then spun down at 1000 rpm for 1 minute, the supernatant was removed, 1 ml of TrypLE Express was added, the pellet was loosened by pipetting, and the cells were placed in a 37°C water bath for 2 minutes.
[0152] After disintegrating all pellets by pipetting, 1.5 ml of basal medium (OB) was added, spun down at 1000 rpm for 3 min, and 1 to 1.5 ml of CryoStor CS10 (Stem cell Technologies, cryopreservation solution) was added to resuspend. 0.5 ml aliquots were placed into cryotubes, placed in freezing containers, and stored in a deep freezer for one day, and then transferred to an LN2 tank for storage the following day.
[0153]
[0154] 3.2. Thawing
[0155] One cryotube was removed from the LN2 tank and melted in a 37°C water bath. When it was about half melted, it was removed from the water bath and transferred to a 15 ml conical tube containing 10 ml of the previously prepared basic medium (OB). The composition of the basic medium (OB) is as shown in Table 5 below.
[0156]
[0157] Organoid Base Medium (OB) Advanced DMEM / F12 containing 10 mM HEPES, 1% GlutaMAX, 100 U / ml penicillin-streptomycin
[0158]
[0159] After centrifugation at 1000 rpm for 3 min, the supernatant was removed, and the organoid pellet was resuspended in 1–1.5 ml cold EM containing 20 μM Y27632. 0.5 ml was then dispensed per well into a new 24-well ultra-low attachment plate.
[0160] Cultured for 3 to 4 days in a 37℃, 5% CO2 incubator, the plates were placed in the incubator, and the organoid fragments were evenly distributed to prevent clumping before closing the door. After 3 to 4 days, the plates were replaced with EM medium and cultured.
[0161]
[0162] Example 4. Liver organoid differentiation (maturation)
[0163] A rough outline of the differentiation process from hepatic endoderm organoids (HEO) to hepatic organoids (HO) is shown in Figure 2.
[0164] As shown in Example 2, HEO subculture was performed, and on days 0 to 2 of subculture, 25 ng / ml BMP7 was added to the EM medium during subculture and cultured for 2 days.
[0165]
[0166] 4.1. Original Method
[0167] On days 2 to 6, after replacing the medium, 25 ng / ml BMP7 was added to the EM medium and cultured for 2 days. On days 6 to 21, the medium was replaced with liver organoid differentiation medium (DM medium), and cultured for 15 days, with the medium replaced at 3-day intervals. The composition of the DM medium is shown in Table 6 below.
[0168]
[0169] Organoid differentiation medium (DM) Advanced DMEM / F12 containing 10 mM HEPES, 1% GlutaMAX, 100 U / ml penicillin-streptomycin, 0.1% BSA, 1% B27 supplement minus vitamin A 25 ng / ml BMP7 100 ng / ml FGF 19 25 ng / ml HGF 1.25 mM N-acetyl-L-cysteine 0.5 μM A83-01 10 uM DAPT 3 μM Dexamethasone 0.5 mg / ml Matrigel GFR
[0170]
[0171] The medium replacement method is based on 1 well of a 24-well plate. Using 1000P, collect all the medium containing the organoids cultured in suspension, transfer them to a 1.5 ml tube, and spin down at maximum speed of 5000 rpm. Afterwards, remove the supernatant, resuspend in 0.5 ml of dedicated EM+ BMP7 or DM, and spread them back onto the plate. Incubate in a 37°C, 5% CO2 incubator. Before placing the plate in the incubator and closing the door, evenly distribute the organoids to prevent clumping.
[0172]
[0173] 4.2. Matrigel-Free Method
[0174] On days 2 to 6, 25 ng / ml BMP7 was added to EM medium without Matrigel in a bioreactor-compatible tube, and the spun-down organoids were added. The tubes were then placed in a bioreactor and cultured at 37°C, 5% CO2, and 80 rpm for 3 days. A CERO 3D incubator & bioreactor was used as the bioreactor.
[0175] On days 6 to 21, the medium was replaced with DM medium without Matrigel, and cultured for 15 days at 37°C, 5% CO2, 60 rpm for 3 days, and the medium was replaced at 3-day intervals.
[0176] The medium replacement method involved leaving the tube containing the organoids cultured in the bioreactor on a clean bench for 1 minute, removing the supernatant (excluding the settled organoids), and adding medium without Matrigel. Afterwards, the tube was capped and placed back into the bioreactor to replace the medium.
[0177]
[0178] Example 5. Analysis of liver organoid characteristics
[0179] 5.1. Observation of liver organoid differentiation results and confirmation of liver organoid characteristics
[0180] According to the above examples 4.1 and 4.2, liver organoids were differentiated, and the differentiation morphology of the liver organoids was observed by measuring it using a phase contrast microscope during the differentiation process.
[0181] Figure 3A shows observations of cells cultured in Matrigel after initially seeding them as single cells. Cells in an EM+BMP7 medium were observed two days after seeding as single cells. Thereafter, the cells were cultured in a bioreactor in a medium containing Matrigel (Example 4.1, Figures 3B and 3C) and a medium without Matrigel (Example 4.2, Figures 3D and 3E).
[0182] As shown in Fig. 3B and Fig. 3D, the liver organoids were observed before differentiation in differentiation medium on day 8 in EM+BMP7, and after differentiation in DM medium on day 8 in EM+BMP7 and on day 15 in EM+BMP7, as shown in Fig. 3C and Fig. 3E. The observation results confirmed that there were morphological differences in the liver organoids produced by the method of differentiation on a bioreactor in a medium without Matrigel (Fig. 3E) and the method of static differentiation in a medium with Matrigel (Fig. 3C).
[0183] In addition, to confirm the characteristics of differentiated liver organoids, after culturing according to Examples 4.1 and 4.2, the organoids were each subjected to fluorescent staining on the 15th day after final differentiation. As a result, it was confirmed that both liver organoids differentiated according to Examples 4.1 and 4.2 well expressed albumin (ALB) protein, alpha-1 antitrypsin (AAT), and hepatocyte nuclear factor 4 alpha (HNF4A). In addition, when FACS was performed on each liver organoid, it was confirmed that albumin expression was high at 94.3% and 98.2%, respectively (Fig. 4).
[0184]
[0185] 5.2. Confirmation of changes in expression of key liver genes in liver organoids
[0186] According to the above examples 4.1 and 4.2, liver organoids were differentiated, and changes in the expression of major liver genes in the differentiated liver organoids were measured.
[0187] Specifically, we identified changes in the expression of genes including liver marker genes ALB, AAT, HNF4A, TDO2, G6P, PCK2, and ASGR1; CYP450 genes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5; and drug transporter genes MDR1, MRP2, BSEP, NTCP, BCRP, OATB1B1, and OATP1B3.
[0188] As a result, as shown in Fig. 5, when liver organoids were differentiated using the Matrigel-Free method according to Example 4.2, compared to when liver organoids were differentiated using the existing method according to Example 4.1, it was confirmed that among the genes listed above, the expression levels of the major liver genes AAT, G6P, PCK2, and ASGR1; the CYP450 genes CYP2B6, CYP2C8, CYP2C19, CYP3A4, and CYP3A5; and the drug transporter genes MDR1, MRP2, NTCP, and BCRP were significantly increased.
[0189] Similarly, when the expression levels according to the number of differentiation days were measured, as shown in Fig. 6, it was confirmed that the expression levels of the major liver genes AAT, TDO2, TAT, and PCK2; the CYP450 genes CYP2C9, CYP2C19, CYP2D6, and CYP3A4; and the drug transporter genes MRP2 and NTCP significantly increased among the genes listed above.
[0190]
[0191] 5.3. Results of measurement of urea secretion capacity and drug-metabolizing enzyme CYP activity according to liver organoid culture method
[0192] According to the above examples 4.1 and 4.2, the liver organoids were finally differentiated for 15 days, and the albumin and urea secreted from the differentiated liver organoids were measured.
[0193] As a result, as shown in Figures 7A and 7B, it was confirmed that the amount of urea secreted from liver organoids significantly increased when liver organoids were differentiated using the Matrigel-Free method compared to the conventional liver organoid production method.
[0194] In addition, the substrate corresponding to each CYP was treated, and the amount of each CYP metabolism was measured using LC-MS / MS at each time point. As a result, as shown in Fig. 7C, in the case of CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, the amount of metabolites produced for the substrates specific to each CYP isoform increased more in the liver organoids produced using the Matrigel-free method than in the conventional liver organoid production method. In particular, a significant increase in CYP3A4 enzyme activity was confirmed through the amount of metabolite produced.
[0195] Additionally, to determine how similar the manufactured liver organoids are to primary human hepatocytes (PHH), the liver organoids after terminal differentiation were treated with midazolam, a substrate of CYP3A4, and the production of CYP3A4 metabolites was measured using LC-MS / MS in the medium at different time points.
[0196] As a result, as shown in Fig. 8, it was confirmed that the amount of metabolites was significantly increased when liver organoids were differentiated using the Matrigel-Free method compared to liver organoids manufactured using the conventional method, and it was confirmed that the results were similar to those of primary cultured human hepatocytes (PHH), specifically PHH1 and PHH2.
[0197]
[0198] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for maturing a liver organoid, comprising a step of culturing a liver endoderm organoid differentiated from a human pluripotent stem cell (hPSC) in a maturation medium that does not contain an extracellular matrix to mature it into a hepatic organoid (HO).
2. In paragraph 1, A method for maturation of liver organoids, wherein the extracellular matrix is matrigel.
3. In paragraph 1, A method for maturing liver organoids, wherein the step of maturing into the above liver organoids is performed using a bioreactor.
4. In paragraph 3, A method for maturation of liver organoids, wherein the revolutions per minute (rpm) of the bioreactor is 50 to 90 rpm.
5. A method for producing a liver organoid, comprising the step of producing a liver organoid by culturing a liver endoderm organoid differentiated from a human pluripotent stem cell in a medium not containing an extracellular matrix.
6. In paragraph 5, A method for producing a liver organoid, wherein the extracellular matrix is matrigel.
7. In paragraph 5, A method for producing a liver organoid, wherein the step of producing the above liver organoid is performed using a bioreactor.
8. In paragraph 7, A method for producing liver organoids, wherein the revolutions per minute (rpm) of the bioreactor is 50 to 90 rpm.
9. In paragraph 5, The above manufacturing method is, (a) A step of differentiating human pluripotent stem cells (hPSCs) into definitive endoderm (DE) cells; (b) a step of differentiating the complete endoderm cells of step (a) into hepatic endoderm cells (HE); and (c) a step of differentiating the hepatic endoderm cells of step (b) into hepatic endoderm organoids (HEO); A method for producing a liver organoid, comprising culturing a liver endoderm organoid obtained through a method in a medium that does not contain an extracellular matrix to produce a liver organoid.
10. In paragraph 9, A method for producing a liver organoid, further comprising, after the step (c) above, a step of subculturing the liver endoderm organoid.
11. In paragraph 10, A method for producing liver organoids, wherein the split ratio during the above subculture is 1:6 to 1:
10.
12. In paragraph 10, A method for producing liver organoids, comprising a step of adding TrypLE Express, Accutase or 0.25% trypsin-EDTA during the above subculture.
13. In paragraph 9, A method for producing a liver organoid, further comprising, after the step (c) above, a step of cryopreserving and thawing the differentiated liver endoderm organoid.
14. A liver organoid produced by the method for producing a liver organoid according to any one of claims 5 to 13.
15. In paragraph 14, A liver organoid, wherein the liver organoid expresses an increased amount of cytochrome P450 (CYP450) compared to liver organoids cultured in a medium containing an extracellular matrix.
16. In paragraph 15, A liver organoid, wherein the cytochrome P450 is at least one selected from the group consisting of CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5.
17. In paragraph 14, The liver organoid expresses alpha-1 antitrypsin (AAT), glucose-6-phosphate (G6P), phosphoenolpyruvate carboxyinase 2 (PCK2), or asialoglycoprotein receptor 1 (ASGR1).
18. In paragraph 17, Liver organoids wherein the above expression is expressed at a higher level compared to liver organoids cultured in a medium containing extracellular matrix.
19. In paragraph 14, The liver organoid expresses multidrug resistance 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), sodium taurocholate co-transporting polypeptide (NTCP), or breast cancer resistance protein (BCRP).
20. In paragraph 19, Liver organoids wherein the above expression is expressed at a higher level compared to liver organoids cultured in a medium containing extracellular matrix.
21. In paragraph 14, A liver organoid, wherein the liver organoid secretes an increased amount of factors compared to liver organoids cultured in a medium containing an extracellular matrix.
Citation Information
Patent Citations
Apparatus for planning cutting path of surgical robot, and mehtod thereof
KR1020240041681A
Method for preparing liver organoid comprising stem cell derived from liver and use thereof
KR102107057B1
KR20220102581A
KR20220121021A
Cited By
Preparation method of liver organ containing interstitial substance
CN119842594A
